Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
Journal of Gastroenterology|August 1, 2023
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varicesFujimasa Tada, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2021
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progressionAtsushi Hiraoka, Takashi Kumada, Takeshi Hatanaka, et al.
Alimentary Pharmacology & Therapeutics|May 8, 2024
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trialToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Liver Cancer|May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in LenvatinibMassimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Reports (Hoboken, N.J.)|April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancers|September 9, 2023
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective StudyKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Cancer Medicine|November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approachTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 19, 2025
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Pageof 17